High-tier generic drug placement in Medicare Part D has increased over time, but it may be related to a drug’s clinical profile and availability of substitutes rather than preferred brand-name drug coverage.
Andrew W. Roberts, PharmD, PhD
Advertisement
Articles by Andrew W. Roberts, PharmD, PhD
Advertisement
Latest Updated Articles
- Trends in Medicare Part D Coverage of Generics With Equivalent Brand-Name Drugs
Published: July 15th 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
3
Radiotherapy Plus Chemo Benefits Certain Patients With DLBCL
4
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
5
